Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

Intravenous OxyContin-associated thrombotic microangiopathy treated successfully without plasma exchange

- Featured Image

In April 2014, in response to intravenous misuse of oral extended-release oxycodone hydrochloride, a new tamper-resistant formulation was released in Australia. We report a case of thrombotic microangiopathy after intravenous misuse of the new tamper-resistant formulation that was successfully managed without plasma exchange.

Clinical record

A 56-year-old man of European ancestry with no clinically significant medical history presented with a 3-day history of periumbilical abdominal pain. He admitted to daily intravenous (IV) misuse of oral extended-release oxycodone hydrochloride (OxyContin; Mundipharma) over a period of months. For the 5 weeks before presentation, he had been injecting the new tamper-resistant formulation because he was unable to access the discontinued crushable form.

On presentation, the patient was afebrile, had a pulse of 95 beats/min, blood pressure of 154/85 mmHg, a respiratory rate of 14 breaths/min and oxygen saturation of 97%. On examination, he had mild periumbilical tenderness. Results of cardiovascular and respiratory examinations were unremarkable. No murmur was detected. There was no injection site infection or axillary lymphadenopathy.

Laboratory investigations showed a haemoglobin level of 87 g/L (reference interval [RI], 135–180 g/L), a total white cell count of 15.0 × 109/L (RI, 4–11 × 10